The One Penny Stock this Billionaire Is Buying Up

Steve Cohen, the legendary billionaire stock picker known for delivering huge returns for his clients at SAC Capital – one of the most successful hedge funds ever – is at it again.

But this time, he’s doing it with his new company Point72 Asset Management – which manages $17.2 billion for high-net-worth individuals.

Even if us normal folks can’t invest in the Point72 fund itself, we can still copy Cohen’s trades…

You see, Point72 is required to disclose all its holding publicly every quarter.

And last quarter, Cohen’s firm revealed a new position in one penny stock that caught my eye.

Here it is…

Cocrystal Pharma Inc. (NASDAQ: COCP)

Cocrystal Pharma is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses.

[finviz ticker=COCP]

The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs.

COCP is currently developing an oral broad-spectrum replication inhibitor called a non-nucleoside inhibitor – which is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of an ultra-short therapy of four to six weeks.

The stock shot up from $0.87 to $2.16 after Cohen announced his stake in the company late last year.

But now that’s it’s down to only $1.40 per share, that makes Cocrystal Pharma one of the more interesting penny stocks to watch for potentially huge gains in 2021.

If those Phase 2 trials turn out successful and the company moves on to Phase 3, the stock should get a boost. And if Phase 3 is successful, the stock could soar.

The Guardian: “New pill could spell the end of aging.”

Sponsored

Take a look at this picture:

This pill is set to completely change the lives of millions of Americans…

And because just one tiny Brisbane company has virtually monopolized this technology with 140 foolproof patents…

Investors who get in on the ground floor stand to become rich beyond their wildest dreams.

Here are all the details.

$2 EV Stock No One's Talking About

This company is a sneaky EV play that no one’s talking about. They’re producing an odd variation on the traditional EV that has consumers raving.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

53-cent Biotech Stock with $2 Price Target

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only 53 cents.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works